Cambridge Healthtech Institute’s 5th Annual

Blood-Brain Barrier

Opportunities, New Targets, Models and Tools, and Delivering Therapy to the Brain

June 19-20, 2019

Antibodies and new drugs that are promising for treating brain diseases and disorders are often limited by poor brain exposure. Research is focused on examining new ways to deliver drugs to the brain, including gene therapy and treatment of the BBB’s microvessels. CHI’s 5th Annual Blood-Brain Barrier conference strives to bring you the hottest topics and biggest opportunities in discovery and development of highly efficacious therapeutic agents against CNS disorders and innovative strategies for delivering therapies across the blood brain barrier (BBB). It will focus on the key areas of understanding BBB transport and dysfunction in disease through a series of case studies and cutting-edge research presentations. This conference will address questions surrounding BBB permeability, blood flow, translational research, and biomarkers of BBB breakdown. Special attention will be paid to in vivo models and tools that are available to investigate BBB transport and pathology in disease. The conference will also provide updates from the industry on antibody delivery and transport across the BBB.

PRECLINICAL TOOLS, BIOMARKERS, ANIMAL AND CELL-BASED MODELS

Differentiation of Human Pluripotent Stem Cells into High Resistance Barrier-Endothelial Cells Using Genome Editing, Genomics and Chemogenomic Library Screening Approaches
Filip Roudnicky, PhD, Senior Scientist, Disease Relevant Cellular Assays, F. Hoffmann-La Roche Ltd.

In vitro and in vivo Models to Evaluate P-gp and BCRP Activity in Regulating BBB Penetration

Guangqing Xiao, PhD, Associate Director, DMPK, Takeda

BBB AT SITES OF PATHOLOGY DURING DISEASE AND INJURY

Integrated Mapping of Pharmacokinetics and Pharmacodynamics in Brain Tumors
Nathalie Y.R. Agar, PhD, Associate Professor, Neurosurgery, Brigham and Women's Hospital

Molecular Mechanisms Governing the Formation and Regulation of the Blood Brain Barrier

Chenghua Gu, DVM. & PhD, Professor of Neurobiology, Harvard Medical School

 

Molecular Insight into Assessment of Unbound Drug Concentration in Brain Regions of Patients with Alzheimer’s Disease

Irena Loryan, PhD, Researcher, Department of Pharmaceutical Biosciences, Translational PKPD, Uppsala University

DRUG DELIVERY AND MOLECULAR TRANSPORT: PRECLINICAL AND CLINICAL UPDATES

IGF1R-Targeting BBB Carrier Antibodies: MOA and Preclinical Assessment

Danica Stanimirovic, MD, PhD, Director, Translational Bioscience Department, Human Health Therapeutics Portfolio, National Research Council of Canada

 

Platform Technology for Treatment of Brain Disorders with Blood-Brain Barrier Penetrating Igg-Fusion Proteins: Preclinical and Clinical Update

Ruben Boado, PhD, Vice President, Research & Development/Co-Founder, ArmaGen, Inc.

For more details on the conference, please contact:Nandini KashyapConference DirectorCambridge Healthtech InstitutePhone: 781-972-5406Email: nkashyap@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-KRod EymaelBusiness Development ManagerCambridge Healthtech InstitutePhone: 781-247-6286Email: reymael@healthtech.com

Companies L-ZJoseph Vacca, M.S.Director, Business Development Cambridge Healthtech InstitutePhone: 781-972-5431Email: jvacca@healthtech.com